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Highlights 
 Management of actinic keratosis lesions is usually based on the clinical 
characteristics of the lesion and the patient’s choice.  
 PDT offers an effective treatment for actinic keratosis lesions. 
 With this technique (PDT) it is possible to treat multiple lesions at the same 
visit. 
 
Abstract 
 
Introduction 
Photodynamic therapy (PDT) is a minimally invasive intervention used in the 
management of tissue disorders. In this retrospective study, a total of 62 patients 
with actinic keratosis (AKs) were treated with surface illumination PDT. Comparisons 
with the clinical features, rate of recurrence as well as malignant transformation and 
overall outcome were made. 
 
Materials and methods 
The medical records of 62 consecutive patients who presented with suspicious skin 
lesions and diagnosed with AKs were examined. These patients with 178 AKs lesions 
were treated with surface illumination methyl aminolevulinate – photodynamic 
therapy (MAL-PDT). The 16% strength cream (MAL) was applied topically 3 hours 
prior to tissue illumination. A single-channel 628nm diode laser was used for 
illumination and light was delivered at 100J/cm2 per site. These patients were 
followed-up for a mean of 7.4 years. 
 
Results 
Eight recurrences were reported after the first round of MAL-PDT, and two 
recurrences after the second round. Malignant transformation to squamous cell 
carcinoma (SCC) was noted in 2 patients only. The 3-year outcome resulted in 60 
patients with complete response (CR), and this was maintained at the final outcome 
(last clinic review). Assessment of lesional outcome vs. response showed that 
175/178 treated lesions had complete response (CR) at 3-year follow-up, which 
increased to 176/178 lesions at the last clinic follow-up. 
 
Conclusion 
MAL-PDT offers an effective treatment for AKs lesions with excellent cosmetic 
outcome. 
 
Keywords: 5-ALA, MAL, PDT, actinic keratosis, NMSC, photodynamic therapy, pre-
cancer, recurrence  
 
 
 
Introduction 
 
Actinic keratosis (AKs), also known as solar keratosis, is considered to be 
precancerous skin condition and can be present in thick patchy, crusty, or scaly form. 
They are commonly known to occur in Caucasians. Frequent exposure to direct 
sunlight is notably a risk factor, due to the damage caused by ultraviolet radiation. If 
left untreated, AKs can progress into squamous cell carcinoma. The malignant 
transformation risk can be up to 20%1,2.  
 
Diagnosis is based on physical examination of the lesion and rarely histopathological 
confirmation is required. Clinically they are often described as having sandpaper–like 
texture with a variety of pigmentary alterations, (i.e. light, dark, tan, red or a 
combination of all) 1,2. Scattered telangiectasias are one of its characteristics, similar 
to basal cell carcinoma. They are generally asymptomatic but many patients 
described lesions with tenderness, itchiness or burning sensation and in some cases 
they tend to bleed. They have been graded clinically depending on their visibility and 
palpability during clinical examination2. There are numerous clinical variants of AKs 
with the “classic” and “hypertrophic” ones being the most common. Others include 
atrophic form, pigmented, AKs with cutaneous horn, actinic cheilitis and Bowenoid 
form. Concern is raised about progression to malignancy if there is induration, 
inflammation, rapid enlargement, bleeding, erythema or ulceration. When there is 
uncertainty during clinical examination, then an incisional biopsy is recommended; it 
is usually taken from the thickest part of the lesion3. 
 
Management of AKs lesions is usually based on the clinical characteristics of the 
lesion and the patient’s choice2.  Medical management was proven to be successful 
when applying topical fluorouracil cream as it blocks the methylation of thymidylate 
synthetase; furthermore, a topical immune-enhancing agent (Imiquimod cream) was 
found to be of use in eliminating these lesions3. Disrupting cell membranes and 
cellular organelles causing cell death was achieved by Ingenol mebutate gel, while 
the diclofenac sodium gel was found to be beneficial as it causes inhibition of the 
arachidonic acid pathway. Retinoids have been introduced and found to be 
advantageous in treating these lesions4.  
 
Cryotherapy is commonly used to treat AKs.  It is usually recommended to treat the 
mild forms of this pathology. Despite having high cure rates, this intervention is not 
commonly advocated nowadays due to side effects including destruction of 
surrounding healthy tissue, skin pigmentation, scarring and blistering.  PDT is now 
commonly used to treat these lesions3. Both topical methyl aminolevulinate (MAL) 
and 5-aminolevulinic acid (5-ALA) have been used as part of this intervention. The 
MAL cream is applied topically over the lesion and the light therapy is delivered after 
few hours.  High cure rates have been achieved using this technique with superior 
cosmetic outcomes3,4. Surgery can always be employed to deal with complex lesions.  
The surgical choices include surgical excision, shave excision and curettage and 
dermabrasion.  Laser therapy is another alternative.  Carbon dioxide (CO2) and 
erbium:yttrium aluminum garnet (Er:YAG) lasers have been used and AK lesions have 
been dealt with by either resection or ablation5. 
 
The clinical course of these lesions varies depending on their characteristics and 
methods of intervention. Regression is most common in patients with few thin 
lesions, while recurrence is higher in patients with thicker symptomatic lesions. 
Patients with complex lesions and high recurrence rate tend to suffer from 
progression to malignancy1,2,3. 
 
In this retrospective study, a total of 62 patients with AKs were treated with surface 
illumination MAL-PDT. Comparisons with the clinical features, rate of recurrence as 
well as malignant transformation and overall outcome were made. 
 
 
Materials and methods 
 
Following a number of prospective ethically approved multicenter trials, PDT was 
approved by the European Medicines Advisory Committee. MAL is approved for the 
use in the management of AK and superficial BCC. The application of PDT at the 
Head and Neck Unit, University College London Hospitals (UCLH) is commonly 
practiced. Most referrals for this tertiary care unit include patients with advanced or 
recurrent disease who failed previous interventions (i.e. surgery, radiotherapy 
and/or chemotherapy) as well as patients with skin pathologies.  
 
PDT is provided as a regular NHS treatment for several superficial and deep-seated 
tissue pathologies. Every treated patient signed an informed consent prior to the 
intervention and was regularly updated on the treatment progress and outcome. 
The patients’ data were entered into proformas, which were validated and checked 
by interval sampling. The fields included a range of clinical, operative and 
histopathological variables. Data collected also included recurrence, malignant 
transformation and last clinic review. 
 
The medical records of 62 consecutive patients who presented with suspicious skin 
lesions and diagnosed with AKs were examined. All patients attending at our 
department undergo full assessment of their skin lesions, which includes physical 
examination, grading, anatomical diagrams and clinical photography as well as 
polarized contact dermoscopy. A surgical biopsy is employed when the diagnosis 
remains uncertain after the clinical assessment. This approach is also employed at 
every follow-up visit. 
 
These 62 patients with 178 AKs lesions were treated with surface illumination MAL-
PDT. These treatments were carried out at the Head and Neck Unit, University 
College Hospital, London between 2006 and 2008. Currently 15-20% of the patients 
we see jointly with our dermatology colleagues elect to receive PDT rather than 
receive conventional therapies. 
  
We used Metvix, which is manufactured by Penn Pharmaceutical Services Ltd. and 
supplied by Galderma. Metvix cream contains methyl aminolevulinate (MAL), which 
is an ester of 5-aminolevulinic acid (5-ALA). It is available as a 16% strength cream in 
a 2g tube.  Common side effects include: pain, mild swelling, skin redness, burning 
sensation and crusting; whilst the least common side effects include blister 
formation, ulceration, skin infection, hyper/hypopigmentation. The manufacturer of 
the laser is Diomed Ltd., Cambridge, UK 
 
These patients were followed-up for a mean of 7.4 years, and biopsies taken in case 
of changes indicative of malignant development. Smoking status was classified into 5 
categories each: life long smoker <20cig/year, life long smoker >20cig/year, ex-
smoker <20cig/year, ex-smoker >20cig/year and non-smoker (Table 1). 
 
A MAL cream was applied topically 3 hours prior to tissue illumination. Early 
application of the photosensitizer would allow the agent to accumulate in the 
pathological area, which would increase the PDT effect. Patients were advised to 
avoid direct sun light exposure for few days after treatment to avoid local tissue 
photosensitive reactions and to allow gradual exposure afterwards.  
 
Very few patients suffering from multiple/extensive AKs were offered the option to 
have the procedure under general anesthetics. It was offered as a day case where 
the patient is brought in the morning and the MAL cream applied and then after 
achieving the drug light interval (DLI), then a treatment is carried out in theatres. If 
the patient recovers well, then plan is set for discharge on the same day after giving 
the full discharge instructions.  
 
On the day of treatment, shielding of the macroscopically healthy surrounding tissue 
is employed. A safety margin of 2mm around the suspicious lesion is included and 
illuminated as part of the treatment. The laser light delivery fibre, with a core 
diameter of 400μm, is usually held directly above the suspect area. A fibre holder 
has been used during all our treatments. The distance from the tip of the fibre to the 
tumour surface is 5cm with up to 3cm spot diameter. A single-channel 628nm diode 
laser was used for illumination and light is delivered at 100J/cm2 per site with a dose 
rate of 50mW/cm2 (Figure 1). 
 
Treatment was repeated to cover larger lesions. Post-PDT pain control was applied 
according to UCLH post-PDT pain protocols. Patients were discharged on the same 
day unless they were required to stay for other reasons (i.e., marked swelling, pain, 
medical issues). 
 
Lesion response evaluation was carried out according to RECIST (Figure 2)- complete 
response (CR): disappearance of all target lesions for at least 4 weeks; partial 
response (PR): at least a 30% decrease in the sum of the longest diameter (LD) of 
target lesions confirmed at 4 weeks; stable disease (SD): neither sufficient shrinkage 
to qualify for PR nor sufficient increase to qualify for progressive disease taking as 
references the smallest sum LD; and progressive disease (PD): at least a 20% increase 
in the sum of LD of target lesions. 
 
Statistical analysis  
The results were analysed by an independent statistician using SPSS 17. The 
outcomes of the categorical clinicopathological variables were summarised as 
frequencies and percentages for the whole group of AKs patients. The numerical 
variables, “age and follow-up”, were summarised by means, standard deviations, 
minimal and maximal values. The results were, also, cross-tabulated to test for 
differences in the case-mix.  
 
Results  
 
The patients’ population comprised 43 males and 19 females. Their mean age at the 
1st diagnosis was 58.9 years. Chronic sun bathing was the most prominent risk factor, 
which was reported by 50 patients. The treated lesions involved most of the body 
sites, with many located over the scalp (n=48), nose (n=32), forehead and peri-
auricular area. Nearly half the cohort had history of AKs, with others reporting 
problems including history of BCC, skin SCC and immunodeficiency. Incisional biopsy 
was required in 18 patients to confirm the diagnosis. Eight recurrences were 
reported after the first round of MAL-PDT, and two recurrences after the second 
round. Malignant transformation to SCC was noted in 2 patients only (Table 1). After 
the first round of treatment, 3 patients reported hypoesthesia and 4 others reported 
hypopigmentation (Table 2). 
 
The 3- year outcome resulted in 60 patients with complete response (CR), and this 
was maintained at the final outcome (last clinic review), (Table 3). Assessment of 
lesional outcome vs. response showed that 175/178 treated lesions had complete 
response (CR) at 3-year follow-up, which increased to 176/178 lesions at the last 
clinic follow-up (Table 4).  
 
Using visual analogue scale (VAS), 53 patients reported that this treatment gave 
them “excellent” cosmetic outcome (VAS 9-10), 5 patients reported it to be “good” 
(VAS 7-8), 2 patients as “fair” (VAS 4-6) and the 2 patients who suffered from 
malignant transformation reported this intervention to be poor (VAS<4). 
 
 
Discussion 
 
PDT is an attractive treatment option for AKs. With this technique it is possible to 
treat large affected skin areas at the same visit. This intervention resulted in high 
cure rates. Wiegell postulated that the efficacy of 5-ALA-PDT and MAL-PDT has been 
established in multiple studies and recommended PDT as a first line therapy in the 
management of these AKs 2.  
 
Treatment outcome in our study utilizing MAL-PDT of 62 patients with AKs showed 
that the majority of patients had complete response (CR) after the first round 
(58/62) and second round (10/12) of treatment. These results were consistent with a 
previous study3; which included 38 patients with AK, subjected to ALA-PDT, were 
randomized to receive a light dose of 70 or 100 J/cm2 as their first split face/scalp 
treatment. Remission at 3 months was 100% and at 6 months was 92.1% for the 
70 J/cm2 cohort; while it was 92.1% (at 3 months) and 84.2% (at 6 months) for the 
100 J/cm2 cohort. The study by Buinauskaite et al. concluded that topical ALA-PDT 
with the red light dose of 70 J/cm2 is an effective treatment for mild and moderate 
face/scalp AKs.  
 
Unpublished data from our institute suggests that light delivery at 100J/cm2 per site 
seems to be leading to a more favourable outcome when managing AK lesions and 
as such we modified the light parameters after discussion with our medical physicists 
(from the licensed protocol of the MAL cream) to ensure enhancing the effect of the 
photochemical process leading to a satisfactory clinical and a cosmetic outcome, 
especially when dealing with the severe face and scalp AKs. From our clinical 
experience and unpublished data, the 100J/cm2 light dose appears to cause more 
satisfactory effect clinically and cosmetically compared to 37 J/cm2 (MAL cream 
licensed protocol) and the 75 J/cm2 recommended by the comparative study of 
Buinauskaite et al., which had a smaller cohort size and based its conclusions on mild 
and moderate face and scalp AKs. 
 
A total of 7 patients only had adverse effects, which included pigmentation changes 
and altered sensation This agreed with previous findings which also suggested 
minimal side effects of PDT3. The reason for these unwanted effects could be due to 
irritation or damage to pigment-producing cells and/or nerve endings at the treated 
site. Efficiency of PDT in treating AK was also reported by retrospective study by Oh 
et al., data analysis of 13 East Asian patients treated with topical MAL-PDT showed 
an overall clearance rate at 3 months of 81.8%4. In addition to high rate of AK 
clearance, malignant transformation was only recorded in 2 patients. Furthermore, 
comparative studies favored PDT over other AK-therapeutic measures. In a meta-
analysis of 641 participants, with a total of 2174 AKs treated with cryotherapy and 
2170 AKs treated with PDT identified PDT to have a better chance (14%) of complete 
lesion clearance at 3 months compared to cryotherapy for thin face and scalp AKs 
lesions5. A Comparative study for the effect of PDT, imiquimod immunotherapy and 
combination of both therapies on 40 lesions of AKs in Japanese patients were 
assessed by Tanaka et al.6. Here severe AK cases were found to respond favorably to 
a combination therapy. Another privilege of PDT was concluded from feedback from 
patients enrolled in this study using VAS, 53 patients (~85%) indicated excellent 
cosmetic outcome, the evaluation by other patients (7) ranged between fair and 
good. Poor results were reported by the 2 patients who suffered malignant 
transformation.   
 
PDT can be delivered under local or general anesthesia and the delivery technique 
can include surface illumination or interstitial application. The selective uptake and 
retention of a locally applied photosensitizer in pathological tissue is an important 
factor in the process7,8. When tumor:normal tissue differentiation has reached an 
optimum, the photosensitizer is activated by non-thermal light of the appropriate 
wavelength. This results either in the production of oxygen free radicals (type I 
mechanism) or the formation of intracellular singlet oxygen (type II mechanism), 
which causes tumor cell death by intracellular oxygenation and vascular shutdown 
mechanisms8-10. 
 
MAL is applied topically. The advantage of topically applied photosensitizer is the 
complete lack of systemic photosensitivity and the fact that MAL-treated patients do 
not have to avoid exposure to light for 2-4 weeks following treatment7,8. The major 
disadvantage of a topically applied photosensitizer is the small treatment depth of 
only 1–2 mm that can be obtained. Therefore, only very superficial lesions of less 
than 1 mm can be treated successfully10-12.  
 
We believe that higher response rates can be achieved using PDT. By careful 
planning and application of the photodynamic process, the cure rates can be very 
high with a very low malignant transformation. The results from this modality are 
comparable to other modalities in achieving excellent clinical and cosmetic outcome. 
However, with PDT the risk of tissue scarring and volume loss are minimal. At this 
stage, there is no evidence to suggest that PDT reduces recurrence rates or 
malignant transformations when compared to other conventional interventions. 
 
In summary, AKs lesions, which are often widespread, can be treated successfully 
with PDT with high cure rate, excellent cosmetic outcomes and minimal adverse 
events.  
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Figure Captions 
Figure 1:  Surface illumination PDT of multiple AK lesions of the scalp. 
Figure 2: Clinical images showing response of thick actinic keratosis lesion to 
photodynamic therapy. 
 
 
Table 1: Demographic details of 62 patients with actinic keratosis treated with 
photodynamic therapy. 
 
 
 Frequency  Frequency 
    
Age at diagnosis   Site (178 lesions)   
Minimum 45 Forehead  12 
Maximum 74 Nose 32 
Mean ±SD (years) 58.9±11.3 Periorbital area 5 
  Upper lip 2 
Gender  Lower lip 7 
Male 43 Cheek   5 
Female 19 Pre-auricular are 15 
  Auricular area  17 
Race  Post-auricular area  8 
Caucasian 58 Scalp 48 
Indian 2 Neck 3 
Middle-Eastern 1 Anterior chest wall 8 
Oriental  1 Posterior chest wall 4 
  Upper limbs  7 
Smoking status  Lowers limbs  5 
Life long smoker <20 12   
Life long smoker >20 11 Relevant Medical history  
Ex-smoker <20 13 Hx of actinic keratosis  27 
Ex-smoker >20 6 Hx of BCC 13 
Non-smoker  20 Hx of skin SCC  19 
  Immunodeficiency 7 
Risk factors     
Chronic sun bathing  50 Need for incisional biopsy  18 
Chronic non-healing wounds 4 Hyperkeratotic AK 7 
Genetic syndromes  0 Pigmented AK 1 
HPV infection  0 Lichenoid AK 9 
Ionizing radiation  2 Atrophic AK 1 
Environmental carcinogens  0   
Artificial UV radiation 0 Primary Rx  
  5-MAL-PDT 62 
Clinical description     
Macules  42 Recurrence after 1st round  8 
Papules  20 Recurrence after 2nd round  4 
  Overall recurrence 3 
Presenting complaint/concern  Overall Malignant transformation  2 
Pain  7   
Itchiness  53 Follow-up  
Bleeding  4 Minimum 48 
Cosmetic  17 Maximum 93 
Fear of malignancy 36 Mean ±SD (months) 88±26.8 
    
Table 2: Side effects reported by patients following treatment of their actinic 
keratosis lesions using 5-MAL photodynamic therapy.  
Side effects – per patient after 1st round of treatment 
  
Anaesthesia  0 
Paraesthesia 0 
Hypoesthesia 3 
Hyperesthesia 1 
Dysesthesia 0 
Hypopigmentation   4 
Hyperpigmentation  1 
Scarring  0 
Ulceration  0 
Transient milia 0 
Rosacea  0 
Recurrence   9 
Malignant transformation 0 
  
 
Table 3: Treatment of actinic keratosis using photodynamic therapy: comparing 
patients versus response. 
 Frequency 
  
Treatment 1  Total of 62 patients 
Complete response  58 
Partial response 2 
Stable disease 2 
Progressive disease (malignant transformation) 0 
  
Recurrence  8 
  
Treatment 2  Total 12 patients 
Complete response  10 
Partial response 0 
Stable disease 1 
Progressive disease (malignant transformation) 1 
  
Recurrence  4 
  
3-year outcome  Total of 62 patients 
Complete response  60 
Partial response 1 
Stable disease 0 
Progressive disease (malignant transformation) 1 
  
5-year outcome  Total of 62 patients 
Complete response  59 
Partial response 2 
Stable disease 0 
Progressive disease (malignant transformation) 1 
  
Final outcome  Total of 62 patients 
Complete response  60 
Partial response 0 
Stable disease 0 
Progressive disease (malignant transformation) 2 
  
Overall recurrence 3 
  
 
Table 4: Treatment of actinic keratosis using photodynamic therapy: comparing 
number of lesions versus response. 
 Frequency 
  
Treatment 1  Total of 178 AKs 
Complete response  167 
Partial response 8 
Stable disease 3 
Progressive disease (malignant transformation) 0 
  
Recurrence  9 
  
Treatment 2  Total of 20 AKs 
Complete response  18 
Partial response 0 
Stable disease 1 
Progressive disease (malignant transformation) 1 
  
Recurrence  5 
  
3-year outcome  Total of 178 AKs 
Complete response  175 
Partial response 2 
Stable disease 0 
Progressive disease (malignant transformation) 1 
  
5-year outcome  Total of 178 AKs 
Complete response  173 
Partial response 4 
Stable disease 0 
Progressive disease (malignant transformation) 1 
  
Final outcome  Total of 178 AKs 
Complete response  176 
Partial response 0 
Stable disease 0 
Progressive disease (malignant transformation) 2 
  
Overall recurrence 5 
  
 
 


